MidYear 2019 Review and Migraine

The July/August 2019 issue overviews developments in the neuro sector YTD, including coverage of paradigm shifts in the treatment of depression, SMA, and migraine. Capsule summaries for 80+ companies are included, plus commentary regarding trends in investment and partnership dynamics. Migraine is reviewed in full for the first time in four years, with an assessment of the CGRP-target reconfiguration of the migraine market, both via the injectibles and the coming oral options from Allergan and Biohaven. The July/August issue also provides an overview of E-Scape Bio.